SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nanjing Leads Biolabs Reports 8.7-Month Median Survival in EP-NEC Trial

Nanjing Leads Biolabs reported median survival of 8.7 months with LBL-024 in a late-line EP-NEC trial.

Related stories